ITGR

Business Context and Reporting Period

Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 26, 2008 (Third Quarter)
Business Overview: Greatbatch designs and manufactures high-quality products for cardiac, neuromodulation, orthopedic, and commercial markets. The company operates two segments: Implantable Medical Components (IMC) and Electrochem. The reporting period reflects significant growth driven by the integration of acquisitions made in 2007 and early 2008, specifically P Medical Holding SA (Precimed) and the DePuy Orthopedics Chaumont Facility, which added an orthopedic product line.

Key Financial Metrics

Note: Working Capital calculated as Current Assets ($218,414) minus Current Liabilities ($89,137).

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 72% in Q3 2008 compared to Q3 2007, driven primarily by the inclusion of Precimed and Chaumont Facility revenues ($48.7 million incremental). Excluding acquisitions, organic sales grew 12%.
• Profitability: While Net Income increased 53% in Q3, the nine-month Net Income decreased 18% to $10.1 million. This decline is attributed to significant non-recurring charges in 2007 (gain on extinguishment of debt and gain on sale of investment security) and higher acquisition-related integration costs in 2008.
• Debt Levels: Long-term debt increased by approximately $111 million to $352.3 million, primarily due to $117 million borrowed under the revolving credit facility to fund the Precimed and Chaumont acquisitions.
• Cost Structure: Cost of sales as a percentage of sales increased from 63.1% in Q3 2007 to 69.4% in Q3 2008. Management attributes this to the lower initial margins of acquired businesses and inventory step-up amortization.

Guidance, Outlook, and Risks

Guidance and Outlook

• 2008 Sales: Management remains comfortable achieving the original guidance of $490 million to $530 million.
• 2009 Sales: Projected revenue growth to the range of $570 million to $610 million.
• Integration: The company expects to continue incurring integration costs for the remainder of 2008 and into the first half of 2009. Consolidation initiatives are expected to improve operating margins over the next two years.

Risks and Contingencies

• Patent Litigation: Enpath (a subsidiary) was found to infringe on Pressure Products Medical Supplies patents. A jury awarded $1.1 million in damages. Sales of the ViaSeal product are enjoined, and FlowGuard sales are permitted only if a royalty is paid into an escrow fund ($1.50-$2.25 per unit). Enpath has appealed the verdict.
• Customer Concentration: Four customers accounted for 55% of total sales in the first nine months of 2008 (down from 67% in 2007).
• Raw Materials: The company relies on a limited number of suppliers for critical raw materials (including precious metals), exposing it to price volatility.
• Accounting Changes: Adoption of FSP APB 14-1 in 2009 is expected to increase non-cash interest expense by $7-$8 million and reduce diluted EPS by approximately $0.19 to $0.22 per share.

Investor Verification Checklist

• Acquisition Integration: Verify the timeline and cost realization of the "Lean" manufacturing and consolidation initiatives intended to improve margins on acquired businesses.
• Litigation Status: Monitor the appeal of the Pressure Products patent infringement case and the potential impact of the escrow royalty payments on the FlowGuard product line.
• Debt Covenants: Confirm continued compliance with the Credit Facility covenants, specifically the adjusted EBITDA to interest expense ratio (minimum 3.00:1) and total leverage ratio (maximum 5.00:1).
• 2009 Accounting Impact: Assess the financial impact of the upcoming FSP APB 14-1 adoption on 2009 interest expense and EPS.
• Customer Diversification: Track progress in reducing reliance on the top four customers, which currently represent over half of total revenue.